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1. Introduction 
Cancer chemotherapeutic agents are not selective 
in their action against cancer cells. Therefore, the 
possibility of using a macromolecule, such as an anti- 
body molecule, as a specific carrier of antitumor 
drugs has attracted considerable attention [ 1,2]. For 
instance, daunorubicin was covalently linked to anti- 
bodies [3-61 or to Fab dimers [7] or to a lectin [8] 
by coupling methods using glutaraldehyde, carbo- 
diimide and periodate oxidation of the drug. For 
technical reasons, and because the activity of a drug is 
partially or totally lost when it is substituted or 
chemically modified, we devised a spacer arm such 
that the drug-carrier conjugate is stable in serum and 
can be specifically split by lysosomal proteases lead- 
ing to the free drug inside the target cells. 
2. Materials and methods 
2.1 . Materials 
Daunorubicin-HCl was kindly provided by Rhone- 
Poulenc, Vitry-sur-Seine. D-Glucose,N-acetylglucos- 
amine, CB, trypsin and WGA, prepared as in [9] were 
purchased from IBF-Reactifs, Pharmindustrie, 
Villeneuve-la-Garenne. L-Arginyl-L-leucine was pur- 
chased from Serva. Iodoacetic acid, N-hydroxysuc- 
cinimide and dicyclohexylcarbodiimide were from 
Aldrich. Di-N-methylformamide, from Merck, was 
Abbreviations: A, spacer arm [ 2-(l-thio$-D-glycopyranosyl)- 
ethanoyl-L-arginyl-L-leucinej (VI); D, daunorubicin; 
A-D, daunorubicin-substituted spacer arm; S-; succinyl; 
WGA, wheat germ agglutinin; SWGA, succinyl wheat germ 
agglutinin; CB, di-N-acetylchitobiose 
refluxed over N-carbobenzoxyglycine-p-nitrophenyl- 
ester and distilled before use. 
Solvent mixtures: (A) chloroform/methanol/water, 
80:30:3, (by vol.);(B) chloroform/methanol/acetic 
acid, 6:3: 1 (by vol.); (C) n-butanol/ethanol/acetic 
acid/water, 5:2:1:2 (by vol.). 
2.2. Preparation of the spacer arm: Glc-S-Et-Arg- 
Leu (VI) 
2,3,4,6 Tetra-O-acetyl+D-glucopyranosyl iso- 
thiouronium (I) [IO] was allowed to react with 
sodium iodoacetate to form 2-(2,3,4,6-tetraa-acetyl- 
1 -thio&D-glucopyranosyl)-ethanoate (II). Com- 
pound II was de0acetylated by treatment with 
sodium methoxide leaving 2-( 1 -thioQ-D-glucopy- 
ranosyl-ethanoate (III) of which the hydroxysuc- 
cinimide ester (compound IV) was prepared. Finally, 
compound IV was reacted with the dipeptide L-argi- 
nyl-L-leucine leading to compound VI (fig.1). Com- 
plete data about the synthesis of compound VI will 
be described elsewhere. 
2.3. Preparation of the spacer arm-drug conjugate: 
Glc-S-Et-Arg-Leu-D (VIII) 
Compound VI (5 18 mg, 1 mmol) was dissoved in 
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Fig.1. Structure of compound VI, 2-(1-thioQ-D-glucopyran- 
osyl)-ethanoyl-L-arginyl-L-leucine (Glc-S-Et-Arg-Leu). 
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di-N-methylformamide (4 ml) and N-hydroxysuc- 
cinimide (138 mg, 1.2 mmol) was added. The solu- 
tion was cooled at 4°C and dicyclohexylcarbodiimide 
(250 mg, 1.2 mmol) was added. After 16 h, the pre- 
cipitate of dicyclohexylurea was removed by filtra- 
tion. To 1 ml solution of the hydroxysuccinimide 
ester (0.25 mmol) of compound (VI), was added 
daunorubicin-HCl (110 mg, 0.2 mmol) (VII) in 
di-N-methylformamide (1 ml); the solution was main- 
tained at pH 9.0 by addition of triethanolamine. This 
solution was stirred at 25°C for 16 h and compound 
(VIII) was isolated by chromatography on a column 
(40 X 3 cm) of silica-gel using solvent mixture (A) 
(180 mg, 0.18 mmol, yield 90%). 
2.4. Preparation ofadaunorubicin-arm-succinylated 
wheat germ agglutinin 
Compound VIII (180 mg, 0.18 mmol) was dis- 
solved in 3 ml 0.2 M sodium acetate buffer (pH 5.0). 
Sodium periodate (128 mg, 0.6 mmol) was added and 
the solution stirred at O”C, in the dark, for 6 h. KC1 
(100 mg, 0.57 mmol) was added, and the precipitate 
of potassium periodate removed by centrifugation. 
The supernatant (850 ~1) was added to a solution 
of wheat germ agglutinin (36 mg, 1 pmol) in 2.5 ml 
saturated sodium carbonate (pH 9.5). The solution 
was kept at 25°C for 6 hand then sodium borohydride 
(4 mg, 0.1 mmol) was added, and the solution was 
kept at 25’C for 1 h. The solution was brought to 
pH 4.5 by addition of acetic acid. The DAC was puri- 
fied by affinity chromatography on immobilized 
p-aminophenyl-I -(thio-N-acetyl-fl-D-glucosaminide) 
(91. 
The DAC was succinylated twice under the condi- 
tions in [ 111 and the SWGA-A-D was dialized 
against distilled water and freeze dried. 
2.5. Effect of D-A-SWGA on L 1210 cells 
Mouse leukemia L 1210 ceils, derived from in vivo 
passaged ascites tumor lines in DBA/2 mice, were 
grown in vitro in RPM1 1640 medium (Gibco) supple- 
mented with L-glutamine and 10% heat-inactivated 
foetal calf serum (Rehatuin, IBF-RBactifs, Pharm- 
industrie) and 1% antibiotic and antimycotic solu- 
tion (Gibco). The doubling time of exponentially- 
growing cells was 12 h. 
2.5.1. Cytotoxic activity 
Cells were suspended in RPM1 ,medium supple- 
mented with foetal calf serum at 8 X 10’ cells/ml 
182 
and dispensed into the wells of a flat bottom micro- 
titer plate in 50 ~1 aliquots. The drug solution in the 
growth medium (50 ~1) was added and the plates 
were incubated at 37’C in a 5% COz atmosphere 
incubator for 4 h or 24 h. The cytotoxicity was esti- 
mated by erythrosin or trypan blue uptake and exclu- 
sion. 
2.5.3. Fate of the SWGA-A-D 
Cells (2 X 106) in 100 pl phosphate-buffered 
saline were incubated at 37’C in the presence of 
daunorubicin and of the various peptide and protein 
derivatives for 30 min, 1 h, 2 h, 4 h or 8 h. At the end 
of the incubation, the supernatant was collected and 
cells were washed 3 times with PBS (1 ml). The 
aqueous supernatant was extracted with 0.3 ml 
n-butanol, 3 times. The organic extracts were concen- 
trated to dryness, redissolved in methanol and ana- 
lyzed by thin-layer chromatography (solvents A$). 
The spots are localized under W light, and were 
scraped off rom the plate. The compounds were 
extracted from the silica-gel using the solvent mixture 
(B). The various organic extracts were concentrated 
to dryness and the residues were dissolved in meth- 
anol (1 ml). The concentration of daunorubicin was 
assessed by spectrofluorimetry, h,,, = 495 nm, h,, = 
595 nm. 
The cell pellets were extracted with 1 ml chloro- 
form/methanol (2: 1, v/v), 3 times. The organic 
compounds were separated and analyzed as above. 
Trypsin hydrolysis was carried out at pH 8.5 in 
0.05 M Tris-HCI, 0.15 M NaCl buffer (2 pg trypsin/ 
ml). 
2.6. Fluorescence microscopy 
L 1210 cells (5 X IO6 cells/ml) were incubated 
with daunorubicin or its derivatives (3 pg free or 
bound daunorubicin/ml) for 30 min, 1 h, 2 h and 4h 
at 4°C and at 37°C. Cells were washed 3 times with 
cold PBS. The cells were examined with a Zeiss 
microscope equipped with epifluorescent illumination 
and filters setting for rhodamine fluorescence. 
3. Results 
Compound (VI) 2-(1 -thioQ-D-glucopyranosyl)- 
ethanoyl-L-arginyl-L-leucine] (fig.1) is readily 
soluble in aqueous buffer. Compound VI on silica-gel 
thin-layer chromatography is detectable with Saka- 
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guchi’s reagent showing the presence of an arginine 
residue, and, after treatment with periodic acid, with 
a benzidine reagent showing the presence of the sugar 
residue. Compound VI was found to be very easily 
hydrolyzed and the free leucine and 2-(1 -thio$-D- 
glucopyranosyl)-ethanoyl-L-arginine were detected 
as the only products by thin-layer chromatography. 
Compound VIII which is readily soluble in aque- 
ous buffer was shown to be homogeneous by thin- 
layer chromatography with solvents A-C. 
Upon treatment with trypsin, compound VIII was 
split into 2-( 1 -thio-&D-glucopyranosyl)-ethanoyl- 
L-arginine and L-leucyl-daunorubicin which were 
identified, using controls, by thin-layer chromato- 
graphy . 
After periodate treatment the oxidized compound 
VIII reacted with WGA and the reaction was moni- 
tored by thin-layer chromatography. The WGA-D 
purified by affinity chromatography, was found to 
contain 1.3 rf 0.2 daunorubicin molecule/protein 
molecule. This result was obtained by using the 
equation: 
2.3 X A495 
IE= 
A 250 - 4.75 A.+95 
(1) 
where n is the number of daunorubicin molecules 
bound/protein molecule, 2.3 is the ratio of the molar 
absorbances of daunorubicin at 495 nm (&s = 10 200) 
and of wheat germ agglutinin at 250 nm (ego = 
23 400) and 4.75 is the ratio of the molar absor- 
bances of daunorubicin at 250 nm and at 495 nm. 
When the daunorubicin was >1.5 mol/mol the sub- 
stituted protein was insoluble. 
WGA-A-D as well as its succinylated derivative 
bind to immobilized N-acetylgluocosaminide and 
agglutinate human red blood cells and L 12 10 cells at 
as low as 10 pg/ml. 
The binding and the uptake of SWGA-A-D 
(100 pg SWGA-A-D containing 3 1.18 bound dauno- 
rubicin) was monitored by fluorescence microscopy. 
After 30 min at 4’C or at 37’C, cells were membrane 
labelled. After 1 h at 37”C, the fluorescence was 
mainly present as clusters. After 2 h, cells became 
leaky. The binding and the uptake of SWGA-A-D 
was totally prevented by incubation in the presence 
of 0.1 M di-N-acetylchitobiose. Cells incubated in the 
presence of Glc-S-Et-Arg-Leu-D (3 pg bound 
daunorubicin/ml) were very weakly labelled; cells 
Table 1 
Time course analysis of total daunorubicin concentration 
m the supernatant of L 1210 cells incubates, expressed as ‘% 
of the initial value 
Drug Incubation (h) 
0 0.5 1 2 4 8 
D - 53 47 25 14 4 
A-D - 100 90 88 53 40 
SWGA-A-D(a) 100 57 47 50 50 90 
(b) 0 2 4 8 45 90 
(a) Total concentration of daunorubicin derivatives; (b) 
Concentration of daunorubicin derivatives extractible by 
n-butanol; L 12 10 cells (I X 10’ cells/ml) were incubated 
in the presence of 3 fig free or bound daunorubicin/ml. 
Results are mean values from 3 individual expt. 
incubated with free daunorubicin (3 I.cg/ml) were 
slowly labelled; the fluorescence intensity reached a 
plateau after an incubation of several hours. 
These observations are in good agreement with the 
quantitative measurements of the uptake of SWGA- 
A-D, of daunorubicin and of its derivatives (tables 
1,2). As shown in table 1, the concentration of free 
daunorubicin present in the supernatant, estimated 
Table 2 
Relative composition of daunorubicin and daunorubicin 
derivatives present in the cell pellets as a function of the 
incubation time 
Drug RF Incubation (h) 
0.5 1 2 4 8 
D 0.25 40 50 70 80 90 
0.7 0 0 0 0 10 
A-D 0.25 0 0 0 0 0 
0.65 1 5 10 40 50 
0.75 0 0 0 0 20 
SWGA-A-D 0.25 20 25 30 20 20 
0.65 24 40 34 20 14 
0.70 0 0 0 2 4 
0.75 0 0 4 8 20 
L 12 10 cells (1 X 1 06/ml) were incubated m the presence of 
3 ~g free or bound daunorubicin/ml. Cells were collected by 
centrifugation and washed 3 times with phosphate-buffered 
saline. The pellet was extrated with chloroform/ethanol (2: 1, 
v/v). The organosoluble compounds were analyzed by thin- 
layer chromatography using solvent A. Results are mean val- 
ues from 3 individual expt. 
183 
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by spec~rofluor~~e~~, decreased continuousIy. The 
concentration of Glc-S-Et-Arg-Leu-D decreased 
also, but much more slowly. The supernatant concen- 
tration of daunorubicin in the case of SWGA-A-D 
was mainly due to protein-bound daunorubicin 
during the first hours; the concentration of organo- 
Fig.2 Fluorescence pho~omicro~aphs of L I21 0 cells illCU- 
bated in the presence of: (A) SWGA-A-D (100 @/ml) for 
1 hat 37°C; (B) SWGA-A-D (100 pg/ml) and 0.1 M di-N- 
acetylchitobiose for 1 h at 37°C. 
soluble daunorubicin increased and became the only 
form present at 4-8 h incubation. 
Upon incorporation of SWGA-A-D into the cells, 
daunorubicin was released within the cells as free 
daunorubicin (& 0.25, solvent C), as well as an orga- 
nosoluble derivative having Rf 0.65 similar to that of 
Glc-S-Et-Arg-Leu-D, and an organosoluble deri- 
vative having R, 0.75 similar to that of leucyldauno- 
rubicin. It is noticeable that celfs incubated in the 
presence of Glc-S-Et-Arg-Leu-D did absorb the 
drug but that no trace of free daunorubicin or of 
leucyl daunorub~cin was detected within the first 4 h 
incubation. 
Finally, the cytotoxic effect of SWGA-A-D was 
assessed by measuring the trypan blue exclusion from 
cells incubated in the presence of daunorubicin, the 
Iectin and their derivatives (table 3). The minimal 
concentration of SWGA-A-D expressed as bound 
daunorubicin required to give a similar cytotoxic 
effect is found to be lower than the concentration of 
free drug, especially in the case of short time incuba- 
tion. When used at 3 /.cg bound daunorubicin/ml the 
Glc-S-Et-Arg-Leu-D and SWGA-A-D in the 
presence of 0.1 M di-~-acetyl~hitobiose were not 
cytotoxic. 
Table 3 
Cytotoxicity of daunorubicin and derivatives for L 1210 
cells after 4 h and 24 h mcubation 
Form Drug 
(pg/mBa 
Vtabihty (%) 
4h 24 h 
- 0 100 100 
D 0.09 100 100 
0.4 100 46 
3 96 45 
A-D 3 100 100 
10 95 86 
SWGA + A-D 3 100 100 
SWGA-A-D 0.09 89 73 
0.4 63 42 
3 44 12 
SWGA-A-D + CB 0.09 100 100 
0.4 100 100 
% 
100 86 
SWGA 100 80 
a Expressed as daullorubicin concentration; b concentration 
of SWGA (100 pg/ml) corresponding to that of 3 rg daunoru- 
bicin in SWGA-A-D 
Results are mean vahres from 3 expt. 
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4. Discussion 
The activity of a cytotoxic drug in vitro is mainly 
based on the capability of the drug to enter the cell 
and to act specifically inside the cell. The penetration 
of a drug into a cell depends upon several parameters 
such as hydrophilicity, hydrophobicity, solubility and 
presence of charges. To increase the activity of a drug 
one or several properties may be changed by chemical 
modification. However, such chemical modification 
may induce a decrease of the activity at the level of 
the target reaction inside the cell [ 12,131. The pene- 
tration of a drug may be greatly facilitated if the drug 
is bound to a carrier which is easily internalized 
[2-81. In order to keep the activity of the drug as 
high as possible, the use of a peptide as a spacer arm 
between the drug and the carrier seemed to be con- 
venient. Because of the known activities of lysosomal 
proteases [ 131, a peptide containing an arginine resi- 
due was chosen. Because leucyl-daunorubicin is 
known to be as active as free daunorubicin, the argi- 
nyl-leucine dipeptide seemed to be convenient. 
Finally, compound, VI was selected to test the hypo- 
thesis of the usefulness of a peptide spacer arm. WGA 
could not be used as protein carrier, because this lec- 
tin is cytotoxic by itself. However, SWGA, which has 
many properties in common with the unsubstituted 
lectin, is not cytotoxic at all and so was a suitable 
carrier. The number of daunorubicin molecules 
bound to each protein molecule could not exceed 
1.5 mol/mol because highly substituted WGA is insol- 
uble. Glc-S-Et-Arg-Leu-D is incorporated into 
cells very slowly; furthermore its degradation is still 
slower, no trace of splitting products are found in 
cells within 4 h. These results together with the lack 
of cytotoxicity at <3 pg/ml suggest hat the Glc-S- 
Et-Arg-Leu-D does not meet the specificity require- 
ments of the hydrolytic enzymes. 
SWGA-A-D binds readily to the lectin receptors 
of the cell surface at 4°C as well as at 37°C. This 
binding is reversed by the presence of di-l\r-acetyl- 
chitobiose, a specific inhibitor. When cells are incu- 
bated in the presence of SWGA-A-D and di-N-acet- 
ylchitobiose, no cytotoxic effect was observed. At 
37’C, SWGA-A-D is rapidly internalized, and free 
daunorubicin as well as a small M, derivative are 
found inside the cells within 30 min. After several 
hours, a part of the free daunorubicin is found also 
in the supernatant, and after 8 h, the supernatant 
does not contain any more daunorubicin bound to 
the carrier. It is interesting to notice that the cyto- 
toxic activity of SWGA-A-D is higher than that of 
free daunorubicin, when assayed after 4 h incubation, 
and that the cytotoxic activity of both free daunoru- 
bicin and SWGA-A-D is similar after 24 h incuba- 
tion. These results suggest: 
(i) That the carrier increases the uptake of the drug 
by inducing an endocytosis process; and 
(ii) That the internalized carrier is promptly hydro- 
lyzed, releasing free daunorubicin and small 
molecular weight derivatives. 
So, the covalent binding of daunorubicin to a protein 
carrier via a simple peptide spacer arm allows one to 
introduce the fully active drug inside the cells. In vivo 
experiments based on this drug-arm-carrier system 
require carriers specific for cancerous cells, such as 
monoclonal antibodies [ 14,151. The preparation and 
study of monoclonal antibodies substituted with 
daunorubicin and other drugs via the above described 
peptide (DAC conjugate) may provide a new immu- 
nochemotherapeutic agent with very specific and high 
antitumor activity. 
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